Incyte Corporation (NASDAQ: INCY) reported results from its Phase 3 frontMIND trial showing that tafasitamab combined with lenalidomide plus R-CHOP ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA